Pancreatic Cancer Research

ResearcherColumbia University Irving Medical CenterActive in the last 2 years

William Arthur Hoos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7784-6539; OpenAlex author ID A5018799065. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
  2. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  3. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  4. Early Detection of Pancreatic Cancer: Applying Artificial Intelligence to Electronic Health Records. Co-author DOI 10.1097/mpa.0000000000001882↗
  5. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  6. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients. Co-author DOI 10.1097/mpa.0000000000001330↗
  7. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retro… Co-author DOI 10.1007/s11523-018-0572-3↗
  8. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Co-author DOI 10.1053/j.gastro.2018.05.023↗
  9. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Kno… Co-author DOI 10.18632/oncotarget.13225↗
  10. Pancreatic cancer clinical trials and accrual in the United States. Co-author DOI 10.1200/jco.2013.49.4823↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Albert Fisher · 3 shared papers, 2021–2026 · strength 0.43
  2. Suresh T. Chari · 3 shared papers, 2018–2021 · strength 0.30
  3. Lynn McCormick Matrisian · 4 shared papers, 2013–2021 · strength 0.28
  4. Lola Rahib · 4 shared papers, 2013–2019 · strength 0.28
  5. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.22
  6. Andrew H. Ko · 1 shared paper, 2026 · strength 0.22
  7. Ravi K. Amaravadi · 1 shared paper, 2026 · strength 0.22
  8. Robert A. Wolff · 1 shared paper, 2026 · strength 0.22
  9. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.22
  10. Lacey Padrón · 1 shared paper, 2026 · strength 0.22
  11. Robert H. Vonderheide · 1 shared paper, 2026 · strength 0.22
  12. Alec C. Kimmelman · 1 shared paper, 2026 · strength 0.22
  13. Mark H. O’Hara · 1 shared paper, 2026 · strength 0.22
  14. Barbara J. Kenner · 2 shared papers, 2021 · strength 0.21
  15. Sudhir Srivastava · 2 shared papers, 2021 · strength 0.21
  16. Vay Liang W. Go · 2 shared papers, 2021 · strength 0.21
  17. Ann E. Goldberg · 2 shared papers, 2021 · strength 0.21
  18. Laura J. Rothschild · 2 shared papers, 2021 · strength 0.21
  19. George A. Poultsides · 2 shared papers, 2021–2023 · strength 0.21
  20. Calvin Jay Kuo · 2 shared papers, 2021–2023 · strength 0.21
  21. Joseph M. Herman · 2 shared papers, 2021–2023 · strength 0.21
  22. Michele Cioffi · 2 shared papers, 2021–2023 · strength 0.21
  23. Daniel Tandel Chang · 2 shared papers, 2021–2023 · strength 0.21
  24. Daniel A. King · 2 shared papers, 2021–2023 · strength 0.21
  25. William E. Gillanders · 2 shared papers, 2021–2023 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.